Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02627430
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:09.321202+00:00
Published At
2016-07-26T00:00:00+00:00
Record Updated At
2016-07-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Solid Neoplasm", "Estrogen Receptor Negative", "Fallopian Tube Serous Neoplasm", "HER2/Neu Negative", "Ovarian Serous Adenocarcinoma", "Ovarian Serous Tumor", "Primary Peritoneal Serous Adenocarcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Triple-Negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2016-07-26"
protocolSection.identificationModule.nctId
"NCT02627430"
protocolSection.identificationModule.officialTitle
"A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Adult Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Negative (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Serous Neoplasm (protocolSection.conditionsModule.conditions)
  • HER2/Neu Negative (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Tumor (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Negative (protocolSection.conditionsModule.conditions)
  • Recurrent Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Triple-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.